u/iman_castellanos

holding a dose an extra month is a legitimate answer to bad tolerance

This. Intention-to-treat versus completer analysis routinely moves the headline by several points.

How long was the randomised phase before any extension?

Correction: that stability figure covers the lyophilised powder, not the reconstituted solution. Different claim entirely.

Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.

Open-label extensions lose their randomisation. Anybody still enrolled at week 104 is a selected group and the numbers describe that group.

Ordered from the warehouse in Denmark instead of origin and the transit went from a fortnight to 7 days. Entirely different proposition in August.

That result is preclinical. Worth flagging, since the thread has been reading it as human data.

Combination and monotherapy arms must be read separately.

nl_verzekering is right that the evidence base here is thin. Conclusions should be held loosely.

Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.

Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.

Kept fingersticks alongside the sensor for two weeks to sanity-check it. Worth doing once.

Careful — that is a claim about efficacy and there is essentially no human evidence behind it.

a rough fortnight at each step is normal, a rough three months is not

do not post your own address details when asking

sulphur burps are unpleasant and they are not dangerous

What dose and how many weeks at it before this started?

My stall was eleven weeks. Eleven. Then it moved again without me changing anything at all.

Minor fix — the half-life is about a week, not about a day. The rest of your point stands.

Shipped from regional stock or from origin?

Nothing on this board is legal advice. Where a notice carries a deadline or a consequence, that is a matter for somebody qualified in your own jurisdiction.

hub_ops is right about the programme names.

Disagreeing with this line: that is a relative reduction and the absolute numbers are considerably less dramatic.

Are you eating in the couple of hours before you sleep?

fibre and water before you buy anything to fix it

variability matters as much as the mean

trial populations get support that nobody on this board gets

comparing reta phase 2 to sema phase 3 is comparing different things

Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.

My stall was eleven weeks. Eleven. Then it moved again without me changing anything at all.

Same pattern here. It settled at a stable dose without me doing anything clever.

independent purity data on this compound is thin

if it is severe or persistent that is a clinician question, not a board question

A symptom that begins the day after the shot and fades by day four tracks the exposure curve. One that appears at random in week 65 probably does not, and that is worth saying to a clinician rather than to us.

a warm gel pack tells you the pack failed, not that the material did

Push back: handling advice from one compound does not transfer to another just because both are peptides.

Yes. Week 37 is when almost everybody writes the "is it still working" post, and almost everybody is fine.

Which day of the week relative to the shot does it hit?